Aarhus University Seal

Anders Hammerich Riis

Metformin use and prostate cancer risk

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Metformin use and prostate cancer risk. / Preston, Mark A; Riis, Anders H; Ehrenstein, Vera et al.

In: European Urology, Vol. 66, No. 6, 12.2014, p. 1012-20.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Preston, MA, Riis, AH, Ehrenstein, V, Breau, RH, Batista, JL, Olumi, AF, Mucci, LA, Adami, H-O & Sørensen, HT 2014, 'Metformin use and prostate cancer risk', European Urology, vol. 66, no. 6, pp. 1012-20. https://doi.org/10.1016/j.eururo.2014.04.027

APA

Preston, M. A., Riis, A. H., Ehrenstein, V., Breau, R. H., Batista, J. L., Olumi, A. F., Mucci, L. A., Adami, H-O., & Sørensen, H. T. (2014). Metformin use and prostate cancer risk. European Urology, 66(6), 1012-20. https://doi.org/10.1016/j.eururo.2014.04.027

CBE

Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami H-O, Sørensen HT. 2014. Metformin use and prostate cancer risk. European Urology. 66(6):1012-20. https://doi.org/10.1016/j.eururo.2014.04.027

MLA

Preston, Mark A et al. "Metformin use and prostate cancer risk". European Urology. 2014, 66(6). 1012-20. https://doi.org/10.1016/j.eururo.2014.04.027

Vancouver

Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF et al. Metformin use and prostate cancer risk. European Urology. 2014 Dec;66(6):1012-20. doi: 10.1016/j.eururo.2014.04.027

Author

Preston, Mark A ; Riis, Anders H ; Ehrenstein, Vera et al. / Metformin use and prostate cancer risk. In: European Urology. 2014 ; Vol. 66, No. 6. pp. 1012-20.

Bibtex

@article{00d6e493f4704558b58f3ae6fc177f07,
title = "Metformin use and prostate cancer risk",
abstract = "BACKGROUND: Metformin may decrease prostate cancer (PCa) risk by reducing hyperinsulinemia-associated carcinogenesis or through direct effects on cancer cells.OBJECTIVE: To evaluate the association between metformin use and PCa diagnosis.DESIGN, SETTING, AND PARTICIPANTS: We used the Danish Cancer Registry and the Aarhus University Prescription Database to conduct a nested case-control study among men residing in northern Denmark from 1989 to 2011. We identified 12 226 cases of PCa and used risk-set sampling to select 10 population controls per case (n=122,260) from among men alive on the index date and born in the same year. A sensitivity analysis was conducted using subjects who had prostate-specific antigen (PSA) testing prior to 1 yr before the index date.INTERVENTION: Metformin exposure was assessed using prescriptions redeemed before the index date.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression. The association between metformin use and PCa diagnosis was determined, controlling for diabetes severity and other potential confounders.RESULTS AND LIMITATIONS: Metformin users were at decreased risk of PCa diagnosis compared with never-users (adjusted OR [aOR]: 0.84; 95% CI, 0.74-0.96). Diabetics on no medication (aOR: 0.98; 95% CI, 0.89-1.09) or on other oral hypoglycemics (aOR: 0.98; 95% CI, 0.86-1.10) did not have a reduced risk of PCa, while users of insulin did have a reduced risk (aOR: 0.77; 95% CI, 0.64-0.93). In the PSA-tested group, metformin use was associated with decreased risk of PCa compared with nonuse (aOR: 0.66; 95% CI, 0.51-0.86). Diabetics on no medication (aOR: 1.03; 95% CI, 0.86-1.24), diabetics on other oral hypoglycemics (aOR: 0.92; 95% CI, 0.70-1.20), and insulin users (aOR: 0.83; 95% CI, 0.56-1.24) did not have a statistically significant reduced risk of cancer.CONCLUSIONS: Metformin use was associated with decreased risk of PCa diagnosis, whereas diabetics using other oral hypoglycemics had no decreased risk.PATIENT SUMMARY: We studied the relationship between metformin (a diabetic medication) and prostate cancer in Denmark. We found that metformin reduced the risk of prostate cancer diagnosis, whereas other oral antidiabetic medications did not.",
author = "Preston, {Mark A} and Riis, {Anders H} and Vera Ehrenstein and Breau, {Rodney H} and Batista, {Julie L} and Olumi, {Aria F} and Mucci, {Lorelei A} and Hans-Olov Adami and S{\o}rensen, {Henrik T}",
note = "Copyright {\textcopyright} 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2014",
month = dec,
doi = "10.1016/j.eururo.2014.04.027",
language = "English",
volume = "66",
pages = "1012--20",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier BV",
number = "6",

}

RIS

TY - JOUR

T1 - Metformin use and prostate cancer risk

AU - Preston, Mark A

AU - Riis, Anders H

AU - Ehrenstein, Vera

AU - Breau, Rodney H

AU - Batista, Julie L

AU - Olumi, Aria F

AU - Mucci, Lorelei A

AU - Adami, Hans-Olov

AU - Sørensen, Henrik T

N1 - Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2014/12

Y1 - 2014/12

N2 - BACKGROUND: Metformin may decrease prostate cancer (PCa) risk by reducing hyperinsulinemia-associated carcinogenesis or through direct effects on cancer cells.OBJECTIVE: To evaluate the association between metformin use and PCa diagnosis.DESIGN, SETTING, AND PARTICIPANTS: We used the Danish Cancer Registry and the Aarhus University Prescription Database to conduct a nested case-control study among men residing in northern Denmark from 1989 to 2011. We identified 12 226 cases of PCa and used risk-set sampling to select 10 population controls per case (n=122,260) from among men alive on the index date and born in the same year. A sensitivity analysis was conducted using subjects who had prostate-specific antigen (PSA) testing prior to 1 yr before the index date.INTERVENTION: Metformin exposure was assessed using prescriptions redeemed before the index date.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression. The association between metformin use and PCa diagnosis was determined, controlling for diabetes severity and other potential confounders.RESULTS AND LIMITATIONS: Metformin users were at decreased risk of PCa diagnosis compared with never-users (adjusted OR [aOR]: 0.84; 95% CI, 0.74-0.96). Diabetics on no medication (aOR: 0.98; 95% CI, 0.89-1.09) or on other oral hypoglycemics (aOR: 0.98; 95% CI, 0.86-1.10) did not have a reduced risk of PCa, while users of insulin did have a reduced risk (aOR: 0.77; 95% CI, 0.64-0.93). In the PSA-tested group, metformin use was associated with decreased risk of PCa compared with nonuse (aOR: 0.66; 95% CI, 0.51-0.86). Diabetics on no medication (aOR: 1.03; 95% CI, 0.86-1.24), diabetics on other oral hypoglycemics (aOR: 0.92; 95% CI, 0.70-1.20), and insulin users (aOR: 0.83; 95% CI, 0.56-1.24) did not have a statistically significant reduced risk of cancer.CONCLUSIONS: Metformin use was associated with decreased risk of PCa diagnosis, whereas diabetics using other oral hypoglycemics had no decreased risk.PATIENT SUMMARY: We studied the relationship between metformin (a diabetic medication) and prostate cancer in Denmark. We found that metformin reduced the risk of prostate cancer diagnosis, whereas other oral antidiabetic medications did not.

AB - BACKGROUND: Metformin may decrease prostate cancer (PCa) risk by reducing hyperinsulinemia-associated carcinogenesis or through direct effects on cancer cells.OBJECTIVE: To evaluate the association between metformin use and PCa diagnosis.DESIGN, SETTING, AND PARTICIPANTS: We used the Danish Cancer Registry and the Aarhus University Prescription Database to conduct a nested case-control study among men residing in northern Denmark from 1989 to 2011. We identified 12 226 cases of PCa and used risk-set sampling to select 10 population controls per case (n=122,260) from among men alive on the index date and born in the same year. A sensitivity analysis was conducted using subjects who had prostate-specific antigen (PSA) testing prior to 1 yr before the index date.INTERVENTION: Metformin exposure was assessed using prescriptions redeemed before the index date.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression. The association between metformin use and PCa diagnosis was determined, controlling for diabetes severity and other potential confounders.RESULTS AND LIMITATIONS: Metformin users were at decreased risk of PCa diagnosis compared with never-users (adjusted OR [aOR]: 0.84; 95% CI, 0.74-0.96). Diabetics on no medication (aOR: 0.98; 95% CI, 0.89-1.09) or on other oral hypoglycemics (aOR: 0.98; 95% CI, 0.86-1.10) did not have a reduced risk of PCa, while users of insulin did have a reduced risk (aOR: 0.77; 95% CI, 0.64-0.93). In the PSA-tested group, metformin use was associated with decreased risk of PCa compared with nonuse (aOR: 0.66; 95% CI, 0.51-0.86). Diabetics on no medication (aOR: 1.03; 95% CI, 0.86-1.24), diabetics on other oral hypoglycemics (aOR: 0.92; 95% CI, 0.70-1.20), and insulin users (aOR: 0.83; 95% CI, 0.56-1.24) did not have a statistically significant reduced risk of cancer.CONCLUSIONS: Metformin use was associated with decreased risk of PCa diagnosis, whereas diabetics using other oral hypoglycemics had no decreased risk.PATIENT SUMMARY: We studied the relationship between metformin (a diabetic medication) and prostate cancer in Denmark. We found that metformin reduced the risk of prostate cancer diagnosis, whereas other oral antidiabetic medications did not.

U2 - 10.1016/j.eururo.2014.04.027

DO - 10.1016/j.eururo.2014.04.027

M3 - Journal article

C2 - 24857538

VL - 66

SP - 1012

EP - 1020

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -